Failure Brings Atea and Roche’s COVID-19 Pill Moonshot Down To Earth

Falls Behind Merck’s Rival

 
• By Andrew McConaghie
  
Atea Pharmaceuticals
Atea's antiviral could still help COVID-19 patients, but its pivotal trial results have been set back to the second half of 2022. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip